The prospect of gene therapy for prostate cancer: Update on theory and status

Kenneth S. Koeneman, Jer Tsong Hsieh

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


Molecularly based novel therapeutic agents are needed to address the problem of locally recurrent, or metastatic, advanced hormone-refractory prostate cancer. Recent basic science advances in mechanisms of gene expression, vector delivery, and targeting have rendered clinically relevant gene therapy to the prostatic fossa and distant sites feasible in the near future. Current research and clinical investigative efforts involving methods for more effective vector delivery and targeting, with enhanced gene expression to selected (specific) sites, are reviewed. These areas of research involve tissue-specific promoters, transgene exploration, vector design and delivery, and selective vector targeting. The 'vectorology' involved mainly addresses selective tissue homing with ligands, mechanisms of innate immune system evasion for durable transgene expression, and the possibility of repeat administration.

Original languageEnglish (US)
Pages (from-to)489-494
Number of pages6
JournalCurrent opinion in urology
Issue number5
StatePublished - Sep 5 2001

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'The prospect of gene therapy for prostate cancer: Update on theory and status'. Together they form a unique fingerprint.

Cite this